Poor metabolizers of UGT1A1 face a significantly increased risk of severe neutropenia from irinotecan therapy, making genetic testing crucial for appropriate dose modification.

Blood clots manifest differently in each patient, with symptoms ranging from severe back pain to unexplained bloating, challenging standard diagnostic approaches.

Among patients with early-stage triple-negative breast cancer, the addition of pembrolizumab to standard chemotherapy demonstrated a 4.9 percentage point improvement in 5-year overall survival.

Up to 17% of infants develop milk protein allergy, making it one of the most prevalent gastrointestinal disorders in the first year of life.

Probiotic therapy shows promise in managing thrush infections, even in cases resistant to conventional antifungal medications.

Of 37 clinical questions examined by international experts, only 6 received clear evidence-based recommendations, highlighting significant gaps in UTI management evidence.